Publications by authors named "T Henninger"
The phase 3 SELENE study evaluated ibrutinib + chemoimmunotherapy (CIT; bendamustine and rituximab [BR]; or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) for patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL). Adult patients who had received ≥1 prior line of CIT were randomized 1:1 to oral ibrutinib (560 mg) or placebo daily, plus 6 cycles of BR/R-CHOP. The primary end point was investigator-assessed progression-free survival (PFS).
View Article and Find Full Text PDFArticle Synopsis
- Ibrutinib, a drug targeting Bruton's tyrosine kinase, shows promise when combined with bendamustine and rituximab for older patients with untreated mantle-cell lymphoma.
- In a study of 523 patients aged 65 and older, those receiving ibrutinib experienced significantly longer progression-free survival (80.6 months) compared to the placebo group (52.9 months).
- While overall survival rates were similar, the incidence of serious side effects was slightly higher in the ibrutinib group, but the treatment's safety aligned with established profiles of the drugs involved.
Zymomonas mobilis is a bacterium that can produce ethanol by fermentation. Due to its unique metabolism and efficient ethanol production, Z. mobilis has attracted special interest for biofuel energy applications; an important area of study is the regulation of those specific metabolic pathways.
View Article and Find Full Text PDFParametric amplification of vacuum fluctuations is crucial in modern quantum optics, enabling the creation of squeezing and entanglement. We demonstrate the parametric amplification of vacuum fluctuations for matter waves using a spinor F=2 87Rb condensate. Interatomic interactions lead to correlated pair creation in the mF=±1 states from an initial mF=0 condensate, which acts as a vacuum for mF≠0.
View Article and Find Full Text PDF